Target type: biologicalprocess
The directed movement of alpha-glucosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Alpha-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in an alpha configuration. [GOC:jl, ISBN:0198506732, PMID:9919658]
Alpha-glucoside transport is a crucial process in the metabolism of carbohydrates, particularly in the absorption of dietary sugars. It involves the movement of alpha-glucosides, a group of sugars containing an alpha-glycosidic linkage, across cell membranes. This transport process plays a key role in various physiological functions, including:
**1. Dietary Sugar Absorption:**
The primary function of alpha-glucoside transport is the absorption of dietary sugars, primarily glucose, from the small intestine into the bloodstream. This process is facilitated by specialized transporter proteins located in the intestinal epithelial cells.
**2. Cellular Energy Production:**
Once absorbed into the bloodstream, glucose is transported to various tissues and organs, where it serves as the primary source of energy. The breakdown of glucose via glycolysis and oxidative phosphorylation provides ATP, the energy currency of the cell.
**3. Glycogen Synthesis:**
Excess glucose in the bloodstream can be stored as glycogen, a complex carbohydrate, in the liver and muscles. Alpha-glucoside transport is involved in the uptake of glucose by these tissues for glycogen synthesis.
**Mechanism of Alpha-Glucoside Transport:**
Alpha-glucoside transport is mediated by specific membrane transport proteins that facilitate the movement of sugars across cell membranes. These transporters are classified into two main types:
**a) Sodium-Dependent Glucose Transporters (SGLTs):**
These transporters utilize the electrochemical gradient of sodium ions (Na+) to drive the uptake of glucose. SGLTs are found in the small intestine and proximal tubules of the kidneys, where they play a critical role in glucose absorption.
**b) Glucose Transporters (GLUTs):**
These transporters facilitate the passive diffusion of glucose down its concentration gradient. GLUTs are widely expressed in various tissues, including skeletal muscle, adipose tissue, and the brain, where they mediate glucose uptake for energy production and other metabolic processes.
**Regulation of Alpha-Glucoside Transport:**
The activity of alpha-glucoside transporters is tightly regulated to maintain glucose homeostasis. Several factors influence transporter activity, including:
**a) Insulin:**
Insulin, a hormone secreted by the pancreas, stimulates glucose uptake by increasing the activity of GLUT4 transporters in muscle and adipose tissue.
**b) Glucose Concentration:**
The concentration of glucose in the blood also influences transporter activity. High glucose levels stimulate the expression of SGLTs in the small intestine, increasing glucose absorption.
**c) Other Hormones:**
Other hormones, such as glucagon and cortisol, can also influence alpha-glucoside transport, although their effects are less direct compared to insulin.
**Clinical Significance:**
Disruptions in alpha-glucoside transport can lead to various metabolic disorders, including:
**a) Diabetes Mellitus:**
In type 1 diabetes, the lack of insulin production results in impaired glucose uptake and utilization. Conversely, type 2 diabetes is characterized by insulin resistance, where target tissues become less responsive to insulin, leading to reduced glucose uptake.
**b) Glucose-Galactose Malabsorption:**
This genetic disorder is caused by mutations in the SGLT1 gene, leading to impaired absorption of glucose and galactose from the small intestine.
**c) Renal Glucose Wastage:**
Impaired function of SGLTs in the kidneys can lead to excessive glucose excretion in the urine, resulting in glycosuria.
**Conclusion:**
Alpha-glucoside transport is a vital process that plays a critical role in carbohydrate metabolism, energy production, and glucose homeostasis. Understanding the mechanism and regulation of this process is crucial for comprehending the pathophysiology of various metabolic disorders and developing targeted therapeutic strategies.'
"
Protein | Definition | Taxonomy |
---|---|---|
Sodium/glucose cotransporter 2 | A sodium/glucose cotransporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P31639] | Homo sapiens (human) |
Sodium/glucose cotransporter 1 | A sodium/glucose cotransporter 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P13866] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
phloretin | dihydrochalcones | antineoplastic agent; plant metabolite | |
phlorhizin | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | antioxidant; plant metabolite | |
vexibinol | sophoraflavanone G : A tetrahydroxyflavanone having a structure of naringenin bearing an additional hydroxyl substituent at position 2' as well as a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavandulyl) substituent at position 8'. vexibinol: flavanol from Sophora; structure in first source; RN given refers to (S-(R*,S*))-isomer | (2S)-flavan-4-one; 4'-hydroxyflavanones; tetrahydroxyflavanone | antimalarial; antimicrobial agent; antioxidant; plant metabolite |
2',4',6'-Trihydroxydihydrochalcone | chalcones | ||
2',4',6'-trihydroxychalcone | pinocembrin chalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 2', 4' and 6' respectively. pinocembrin chalcone: isolated from Helichrysum trilineatum; structure in first source | chalcones | antifungal agent; plant metabolite |
sergliflozin etabonate | sergliflozin: a hypoglycemic agent that inhibits SGLT2 sodium-glucose transporter; structure in first source | glycoside | |
remogliflozin etabonate | remogliflozin etabonate: orally administered hypoglycemic agent; structure in first source | glycoside | |
dapagliflozin | aromatic ether; C-glycosyl compound; monochlorobenzenes | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor | |
ipragliflozin | glycoside | ||
empagliflozin | aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor | |
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol | diarylmethane | ||
nothofagin | nothofagin: a dihydrochalcone | ||
canagliflozin | canagliflozin hydrate : A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. | C-glycosyl compound; organofluorine compound; thiophenes | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor |
pf 04971729 | ertugliflozin: structure in first source | diarylmethane | |
deberza | 2-benzofurans |